HPV testing in first-void urine provides sensitivity for CIN2+ detection comparable with a smear taken by a clinician or a brush-based self-sample: cross-sectional data from a triage population

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 124, Issue 9, 2017, Pages 1356-1363

  Leeman, A ^a   del Pino, M ^b   Molijn, A ^a   Rodriguez, A ^b   Torne A ^b   de Koning, M ^a   Ordi, J ^c   van Kemenade, F ^d   Jenkins, D ^a   Quint, W ^a  

^a DDL DIAGNOSTIC LABORATORY   (Netherlands)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cervical intraepithelial neoplasia; human papillomavirus; self sampling; urine

Indexed keywords

VIRUS DNA; BIOLOGICAL MARKER;

ADULT; ASSAY; BRUSH BASED SELF SAMPLING; CANCER GRADING; CLINICIAN TAKEN SMEAR; COHORT ANALYSIS; COLPOSCOPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC TEST; EMERGENCY HEALTH SERVICE; FEMALE; GENOTYPE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION RISK; INTERMETHOD COMPARISON; LETTER; MAJOR CLINICAL STUDY; NONHUMAN; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SMEAR; SPAIN; URINALYSIS; URINE SAMPLING; UTERINE CERVIX CARCINOMA IN SITU; UTERUS BIOPSY; WART VIRUS; ADOLESCENT; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTICENTER STUDY; PAPILLOMAVIRIDAE; PATHOLOGY; PROCEDURES; SELF EVALUATION; URINE; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; CROSS-SECTIONAL STUDIES; DIAGNOSTIC SELF EVALUATION; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TRIAGE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 85024844601     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.14682     Document Type: Letter

References (28)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–86.
2. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004;364:249–56.
3. Kitchener HC, Castle PE, Cox JT. Chapter 7: achievements and limitations of cervical cytology screening. Vaccine 2006;24(Suppl. 3):S3.
4. Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004;110:94–101.
5. Kitchener HC, Almonte M, Gilham C, Dowie R, Stoykova B, Sargent A, et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess 2009;13:1–150, iii–iv.
6. Elfgren K, Rylander E, Radberg T, Strander B, Strand A, Paajanen K, et al. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol 2005;193(3 Pt 1):650–7.
7. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Palma PD, Mistro AD, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11:9.
8. Gok M, Heideman DA, van Kemenade FJ, de Vries AL, Berkhof J, Rozendaal L, et al. Offering self-sampling for human papillomavirus testing to non-attendees of the cervical screening programme: Characteristics of the responders. Eur J Cancer 2012;48:1799–808.
9. Snijders PJ, Verhoef VM, Arbyn M, Ogilvie G, Minozzi S, Banzi R, et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer 2013;132:2223–36.
10. Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol 2014;15:172–83.
11. van Baars R, Bosgraaf RP, ter Harmsel BW, Melchers WJ, Quint WG, Bekkers RL. Dry storage and transport of a cervicovaginal self-sample by use of the Evalyn Brush, providing reliable human papillomavirus detection combined with comfort for women. J Clin Microbiol 2012;50:3937–43.
12. Pathak N, Dodds J, Zamora J, Khan K. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. BMJ 2014;349:g5264.
13. van der Marel J, van Baars R, Quint WG, Berkhof J, del Pino M, Torne A, et al. The impact of human papillomavirus genotype on colposcopic appearance: a cross-sectional analysis. BJOG 2014;121:1117–26.
14. Bornstein J, Bentley J, Bosze P, Girardi F, Haefner H, Menton M, et al. 2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol 2012;120:166–72.
15. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114–9.
16. Geraets DT, Grunberg AW, van der Helm JJ, Schim van der Loeff MF, Quint KD, Sabajo LO, et al. Cross-sectional study of genital carcinogenic HPV infections in Paramaribo, Suriname: prevalence and determinants in an ethnically diverse population of women in a pre-vaccination era. Sex Transm Infect 2014;90:627–33.
17. Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, ter Schegget J, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999;37:2508–17.
18. Meijer CJ, Berkhof H, Heideman DA, Hesselink AT, Snijders PJ. Validation of high-risk HPV tests for primary cervical screening. J Clin Virol 2009;46(Suppl. 3):S1–4.
19. Geraets DT, Heideman DA, de Koning MN, Snijders PJ, van Alewijk DC, Meijer CJ, et al. High-throughput genotyping of high-risk HPV by the digene HPV Genotyping LQ Test using GP5+/6+-PCR and xMAP technology. J Clin Virol 2009;46(Suppl. 3):S21–6.
20. Geraets DT, Cuschieri K, de Koning MN, van Doorn LJ, Snijders PJ, Meijer CJ, et al. Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control. J Clin Microbiol 2014;52:3996–4002.
21. Luo W, Yang H, Rathbun K, Pau CP, Ou CY. Detection of human immunodeficiency virus type 1 DNA in dried blood spots by a duplex real-time PCR assay. J Clin Microbiol 2005;43:1851–7.
22. Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 1968;70:213–20.
23. Bosgraaf RP, Verhoef VM, Massuger LF, Siebers AG, Bulten J, de Kuyper-de Ridder GM, et al. Comparative performance of novel self-sampling methods in detecting high-risk human papillomavirus in 30,130 women not attending cervical screening. Int J Cancer 2015;136:646–55.
24. Burroni E, Bonanni P, Sani C, Lastrucci V, Carozzi F, Hpv ScreeVacc Working G, et al. Human papillomavirus prevalence in paired urine and cervical samples in women invited for cervical cancer screening. J Med Virol 2015;87:508–15.
25. Stanczuk GA, Currie H, Baxter G, Foster A, Gibson L, Graham C, et al. Cobas 4800 HPV detection in the cervical, vaginal and urine samples of women with high-grade CIN before and after treatment. J Clin Pathol 2015;68:567–70.
26. Dijkstra MG, Heideman DA, van Kemenade FJ, Hogewoning KJ, Hesselink AT, Verkuijten MC, et al. Brush-based self-sampling in combination with GP5+/6+-PCR-based hrHPV testing: high concordance with physician-taken cervical scrapes for HPV genotyping and detection of high-grade CIN. J Clin Virol 2012;54:147–51.
27. Darlin L, Borgfeldt C, Forslund O, Henic E, Dillner J, Kannisto P. Vaginal self-sampling without preservative for human papillomavirus testing shows good sensitivity. J Clin Virol 2013;56:52–6.
28. Senkomago V, Des Marais AC, Rahangdale L, Vibat CR, Erlander MG, Smith JS. Comparison of urine specimen collection times and testing fractions for the detection of high-risk human papillomavirus and high-grade cervical precancer. J Clin Virol 2016;74:26–31.